HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Clinical trial NCT03662087 · UNKNOWN

Trial details

NCT number: NCT03662087
Sponsor: Nanfang Hospital, Southern Medical University
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

Start date: 2018-10-01
Primary completion: 2021-10-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.